Hyperlipidaemia News

  • 25 March 2020
    Understanding the genetic cause of familial hypercholesterolaemia (FH, inherited high cholesterol) is imperative to better stratify and manage cardiovascular risk in patients, according to this report from the UK BioBank. FH is the most common inherited metabolic condition, affecting about one in 200-250 people.1 Genetic variants in the LDLR, APOB...
  • 25 March 2020
    Familial hypercholesterolaemia (FH, inherited high cholesterol) is one of the most common inherited disorders, affecting approximately one in every 250 people or over 30 million people worldwide.  FH is usually caused by pathogenic variants in either of the LDLR, APOB or PCSK9 genes (encoding the LDL receptor, apolipoprotein B or PCSK9,...
  • 25 March 2020
    Alirocumab shows benefit in patients with type 2 diabetes mellitus (T2DM) and mixed dyslipidaemia, according to this analysis of the ODYSSEY DM-DYSLIPIDEMIA trial. Individuals with T2DM are at increased risk for atherosclerotic cardiovascular disease (ASCVD), in part due to the mixed dyslipidemia, characterized by elevated triglycerides (TGs) and...
  • 28 February 2020
    Trial BEIJERINCK: A Double Blind, Randomized, Placebo Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy on LDL-C of Evolocumab (AMG 145) in Subjects With HIV and With Hyperlipidemia and/or Mixed Dyslipidemia. ClinicalTrials.gov Identifier: NCT02833844 Aim To investigate the efficacy and safety of evolocumab (420 mg...
  • 28 February 2020
    First trial of PCSK9 monoclonal antibody therapy in people living with HIV and at moderate/high cardiovascular risk, with elevated LDL cholesterol levels has closed enrolment, with 464 patients. Due to advances in antiretroviral treatment, HIV is now regarded as a chronic disease. Consequently, attention has refocused on the associated high...
  • 28 February 2020
    Trial DE LAVAL: A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment. ClinicalTrials.gov Identifier: NCT02585895...
  • 28 February 2020
    Treatment with evolocumab may replace lipoprotein apheresis in patients with high LDL cholesterol levels, refractory to conventional treatment, according to the findings from the DE LAVAL study. Lipoprotein apheresis, which removes LDL cholesterol from the circulation, is indicated in patients with refractory heterozygous familial...
  • 26 February 2020
    A key question posed by all clinicians is whether age or sex impacts the efficacy of a cholesterol-lowering therapy. This is highly pertinent given the ‘greying’ of populations, and the associated increase in risk for cardiovascular events.  A new analysis from the FOURIER study which addressed this question shows that evolocumab is similarly...
  • 26 February 2020
    Renal impairment does not influence the pharmacodynamics/pharmacokinetics of inclisiran, according to a new analysis. Impaired renal function alters drug pharmacokinetics, potentially changing drug efficacy and increasing the likelihood of unwanted effects, including renal toxicity. This is a key consideration for individuals taking long-term...
  • 26 February 2020
    A new statement from the European Atherosclerosis Society (EAS) consensus panel is set to become THE reference for the role of LDL in driving atherosclerosis. Published today in The European Heart Journal, this is an essential follow-up to a previous statement1 which appraised clinical evidence supporting the causality of LDL in atherosclerotic...
  • 26 February 2020
    Professor Eric Bruckert (Hôpital Pitié Salpêtrière, Paris, France) gives his perspective on the take home messages from TAUSSIG.  Patients with homozygous familial hypercholesterolaemia (FH) are extremely difficult to manage. High LDL cholesterol levels associated with this disorder put patients at very high risk of premature coronary heart...
  • 13 February 2020
    TAUSSIG: Evolocumab provides sustained benefit in severe heterozygous or homozygous FH Evolocumab treatment for up to 5 years was effective and well tolerated in patients with homozygous or severe heterozygous familial hypercholesterolaemia (FH, inherited high cholesterol) in this latest follow-up from the TAUSSIG study. Over this time, LDL...
  • 29 January 2020
    Following much discussion among the clinical community, the lipoprotein(a) analysis from the ODYSSEY OUTCOMES study has been published. This analysis shows that lipoprotein(a) lowering by alirocumab is an independent contributor to the reduction in cardiovascular events observed in this trial, beyond that attributed to LDL cholesterol lowering....
  • 29 January 2020
    In a mouse model of hyperlipidaemia, the combination of the PCSK9 inhibitor alirocumab, a monoclonal antibody to ANGPTL3 (angiopoietin-like 3 protein) evinacumab, and atorvastatin not only reduced LDL cholesterol by 73% but also regressed atherosclerosis. Read the article:  Pouwer MG, et al. Alirocumab, evinacumab, and atorvastatin triple therapy...
  • 17 December 2019
    A pre-specified analysis from the ODYSSEY OUTCOMES study shows that, in patients with recent acute coronary syndrome (ACS), alirocumab improves outcomes irrespective of age. Increasing absolute benefit but not harm with advancing age suggests that LDL-C lowering is an important preventive intervention for older patients after ACS. Although LDL-C...
  • 17 December 2019
    Initial results from the GAUSS-4  trial (ClinicalTrials.gov NCT02634580) show that evolocumab was superior to ezetimibe in reducing LDL-C during the 12-week double-blind period in patients with statin intolerance, with efficacy and safety results maintained for 1 year. In patients with hyperlipidaemia, intolerance to statins presents a challenge...
  • 11 December 2019
    A new analysis of the FOURIER trial (in patients with clinically evident atherosclerotic cardiovascular disease) shows that those with high genetic risk, regardless of clinical risk, had a high cardiovascular event rate and derived the greatest relative and absolute benefit from evolocumab. Treatment with evolocumab in those patients at high...
  • 11 December 2019
    Post hoc analyses of the ODYSSEY OUTCOMES trial reveal that a high polygenic risk score (PRS) for coronary artery disease (CAD) is associated with elevated risk for recurrent major adverse cardiovascular events (MACE) after acute coronary syndrome (ACS), and larger absolute and relative risk reduction with alirocumab treatment. These results may...
  • 11 December 2019
    The Treat Stroke to Target trial (ClinicalTrials.gov Identifier: NCT01252875) shows that aggressive LDL-C reduction with a goal of <70 mg/dl is superior to a more modest reduction (LDL-C 90-110 mg/dl) among patients with atherosclerotic cardiovascular disease (ASCVD) and evidence of ischaemic stroke or transient ischaemic attack (TIA). Patients...
  • 04 December 2019
    Reports from the 11th Closed Expert Meeting of the PCSK9 Education and Research Forum Professor Phil Shaul  The post Endothelial LDL transcytosis in atherosclerosis appeared first on PCSK9 Forum.

Pages